Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amatuximab - Eisai

Drug Profile

Amatuximab - Eisai

Alternative Names: Anti-mesothelin monoclonal antibody; MORAb-009; MORAB-009-006

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Cancer Institute (USA)
  • Developer Eisai Co Ltd; Eisai Inc
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Malignant-mesothelioma; Pancreatic cancer; Solid tumours

Most Recent Events

  • 29 Nov 2022 Discontinued - Phase-II for Malignant mesothelioma (Combination therapy, Inoperable/Unresectable, Late-stage disease) in Italy, United Kingdom, Germany, France, Australia, USA (IV)
  • 29 Nov 2022 Discontinued - Phase-II for Malignant mesothelioma in USA, Germany, Canada, Netherlands, Spain (IV)
  • 16 Apr 2021 Amatuximab is still in phase II trials for Malignant mesothelioma in Australia, Canada, France, Germany, Italy, Netherlands, Spain, USA, United Kingdom (Eisai pipeline, April 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top